Tag Archives: tirzepatide
Tirzepatide vs Semaglutide: Liver Outcomes Are Level
Tirzepatide dropped more BMI than semaglutide over 17 months, and hard liver outcomes came out identical: 4.05 versus 4.04 events per 1000 person-years.
Tirzepatide and HFpEF: What 3,308 Matched Patients Show
Tirzepatide-treated men and women with HFpEF differed little on cardiovascular outcomes. The authors say the design cannot show effectiveness by sex.
Tirzepatide and Blood Pressure: 32 Trials, Two Signals
Tirzepatide cut hypertension-related adverse events but raised hypotension-related ones across 32 trials, while semaglutide looked neutral on both counts.
SURMOUNT Post Hoc Analysis: What a Composite Endpoint Does and Does Not Show
A post hoc analysis of four SURMOUNT trials counts participants who reached three targets at the same time. The counting method is worth as much attention as the percentages it produces.
Anti-Obesity Medications and Ageing: What a 2026 Review Reports
A narrative review published in August 2026 maps what anti-obesity medications appear to do beyond weight loss, from cardiovascular outcomes to skin laxity, and states plainly where the evidence stops short.